Age (years) | CINI n (%) | CINII n (%) | CINIII n (%) | ICC n (%) | Total n (%) |
|---|
≤ 29 | 118 (6.18) | 70 (9.75) | 28 (4.86) | 1 (0.21) | 217 (5.91) |
30–39 | 342 (17.91) | 162 (22.56) | 109 (18.92) | 23 (4.89) | 636 (17.31) |
40–49 | 575 (30.10) | 209 (29.11) | 190 (32.99) | 82 (17.45) | 1056 (28.74) |
50–59 | 640 (33.51) | 193 (26.88) | 156 (27.08) | 147 (31.28) | 1136 (30.92) |
≥ 60 | 235 (12.30) | 84 (11.70) | 93 (16.15) | 217 (46.17) | 629 (17.12) |
Total | 1910 (100) | 718 (100) | 576 (100) | 470 (100) | 3674 (100) |
- In the ICC group, the prevalence of HPV was significantly higher in the ≥ 60 years group than that of in other age groups, P < 0.001 (≤ 29 years group, χ2 = 278.64; 30–39 years group, χ2 = 210.58; 40–49 years group, χ2 = 89.39; 50–59 years group, χ2 = 21.97)
- In the CINI group, the prevalence of HPV was significantly higher in the 50–59 years group than that of in other age groups (≤ 29 years group, χ2 = 448.47, P < 0.001; 30–39 years group, χ2 = 121.72, P < 0.001; 40–49 years group, χ2 = 5.10, P = 0.024; ≥ 60 years group, χ2 = 243.15, P < 0.001)
- In the CINII group, the prevalence of HPV was significantly higher in the 40–49 years group than that of in other age groups (≤ 29 years group, χ2 = 85.95, P < 0.001; 30–39 years group, χ2 = 8.03, P = 0.005; ≥ 60 years group, χ2 = 67.00, P < 0.001); except 50–59 years group (50–59 years group, χ2 = 0.88, P = 0.347)
- In the CINIII group, the prevalence of HPV was significantly higher in the 40–49 years group than that of in other age groups (≤ 29 years group, χ2 = 148.48, P < 0.001; 30–39 years group, χ2 = 29.64, P < 0.001; 50–59 years group, χ2 = 4.78, P = 0.029; ≥ 60 years group, χ2 = 44.08, P < 0.001)
